Structure-based design of targeted covalent inhibitors
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [40]
In the citing paper
“Covalent ligand screening is another ligand discovery approach that is becoming more common, whereby various methods are used to discover covalent ligands from libraries of electrophilic compounds7,12,13.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
In the citing paper
“include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (AbbVie) and the epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca), with sales totalling US$8.43 billion and $4.33 billion in 2020, respectively7,8.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Research works printed but not linked: 1
- Martin-Gago, 2017, Cell Chem. Biol., 24, e585
Cited by
Items 201–300 of 371
Gao, W., Yang, X., Li, Q., Liu, Y., Huang, W., Xia, X., & Yan, D. (2025) · Advanced Science · doi:10.1002/advs.202412273 · Cited by 11
Bush, J. T., Leśniak, R. K., Yeh, T.-L., Belle, R., Kramer, H., Tumber, A., Chowdhury, R., Flashman, E., Mecinović, J., & Schofield, C. J. (2018) · Chemical Communications · doi:10.1039/c8cc07706a · Cited by 7
Han, X., Huang, Y., Wei, L., Chen, H., Guo, Y., Tang, Z., Hu, W., Xia, Q., Wang, Q., Yan, J., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115624 · Cited by 8
Aranda-Tavío, H., Recio, C., Martín-Acosta, P., Guerra-Rodríguez, M., Brito‐Casillas, Y., Blanco, R. E., Junco, V., León, J., Montero, J. C., Gandullo‐Sánchez, L., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112330 · Cited by 10
“These findings outline a JKST6 durable action that is normally associated with ligand-target covalent bonds, long drug-target residence, or posttranslational effects after drug-target union [38,39].”
BackgroundJia, X., Xin, M., Xu, J., Xiang, X., Li, X., Jiao, Y., Wang, L., Jiang, J., Pang, F., Zhang, X., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05201-0 · Cited by 9
Visible‐Light‐Induced Cysteine‐Specific Bioconjugation: Biocompatible Thiol–Ene Click Chemistry
Choi, H., Kim, M., Jang, J., & Hong, S. (2020) · Angewandte Chemie · doi:10.1002/ange.202010217 · Cited by 8
Qin, Z., Zhu, Y., & Xiang, Y. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-nd0r2-v2 · Cited by 8
Hu, X., Wu, J., He, Q., Xiong, Z., & Li, N. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101045 · Cited by 7
“Targeted covalent inhibitors have capture growing interest as potential drug candidates due to their bene fi ts in term of high potency and prolonged duration of action [1,2].”
Discovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Quevedo, M. A., & Dehaen, W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00460 · Cited by 8
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Dehaen, W., & Quevedo, M. A. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00631 · Cited by 8
Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding
Morese, P. A., Ahmad, A., Martin, M. P., Noble, R. A., Pintar, S., Wang, L.-Z., Xu, S., Lister, A. S., Ward, R. A., Bronowska, A. K., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01501-6 · Cited by 8
“We studied a congeneric series of analogues of the anilinoquinazoline-basedEGFR TCI poziotinib 11 ( 4 , Fig.”
Self-citationPeptide-Based Targeted Covalent Inhibitors
Cao, F., Guo, R.-C., Zhang, Z., & Yu, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18100 · Cited by 8
Chemo-Selective Cys–Pen Disulfide for Proximity-Induced Cysteine Cross-Linking
Zhan, M., Wang, R. Y., Liu, Z., Liu, N., Ye, Y., Liang, M., Zhang, Y., Jiang, C., Yin, F., & Li, Z. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00083 · Cited by 7
Danilack, A. D., Dickson, C. J., Soylu, C., Fortunato, M., Rodde, S., Münkler, H., Horn̆ák, V., & Duca, J. S. (2024) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-024-00560-6 · Cited by 9
“Covalent drug potency cannot be measured with a simple IC 50 , and the kinetic parameters required to describe potency can be challenging to obtain [6, 9].”
Exploring the binding dynamics of covalent inhibitors within active site of PLpro in SARS-CoV-2
Patel, D. K., Kumar, H., & Sobhia, M. E. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108132 · Cited by 7
Synthesis and Biological Evaluations of Electrophilic Steroids Inspired by the Taccalonolides
Clanton, N. A., Hastings, S. D., Foultz, G. B., Contreras, J. A., Yee, S. S., Arman, H. D., Risinger, A. L., & Frantz, D. E. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00534 · Cited by 7
Sahasrabuddhe, A., Oakley, D., Chen, K., & McCarter, J. D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979596 · Cited by 7
Klose, K., Packeiser, E., Granados-Soler, J. L., Hewicker‐Trautwein, M., Escobar, H. M., & Nolte, I. J. A. (2022) · Veterinary and Comparative Oncology · doi:10.1111/vco.12817 · Cited by 9
Mol’kova, E. A., Shchegravina, E. S., Otvagin, V. F., Kuzmina, N. S., Malysheva, Y. B., Svirshchevskaya, E. V., Zaburdaeva, E. A., & Fedorov, A. Y. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3449-7 · Cited by 7
Serendipitous Identification of a Covalent Activator of Liver Pyruvate Kinase
Battisti, U. M., Gao, C., Nilsson, O., Akladios, F. N., Lulla, A., Bogucka, A., Nain‐Perez, A., Håversen, L., Kim, W., Borén, J., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200339 · Cited by 7
Kinetic Modeling of Covalent Inhibition: Effects of Rapidly Fluctuating Intermediate States
Ghaby, K., & Roux, B. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00952 · Cited by 5
Hu, S., Jiang, C., Gao, M. Q., Zhang, D., Yao, N., Zhang, J., & Jin, Q. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137224 · Cited by 6
Allocolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin
Sazanova, E. S., Gracheva, I. A., Allegro, D., Barbier, P., Combes, S., Svirshchevskaya, E. V., & Fedorov, A. Y. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00060d · Cited by 6
Thiol Reactivity of N-Aryl α-Methylene-γ-lactams: Influence of the Guaianolide Structure
Dempe, D. P., Ji, C., Liu, P., & Brummond, K. M. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01530 · Cited by 7
The Structure–property Relationships of Clinically Approved Protein Kinase Inhibitors
Choi, K. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220822123552 · Cited by 8
Understanding Cysteine Chemistry Using Conventional and Serial X-ray Protein Crystallography
Smith, N., & Wilson, M. A. (2022) · Crystals · doi:10.3390/cryst12111671 · Cited by 7
Measurement and utilization of the proteomic reactivity by mass spectrometry
Punzalan, C., Wang, L., Bajrami, B., & Yao, X. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21837 · Cited by 8
Krymov, S. K., Salnikova, D. I., Dezhenkova, L. G., Bogdanov, F. B., Korlyukov, A. A., Scherbakov, A. M., & Shchekotikhin, A. E. (2023) · Pharmaceuticals · doi:10.3390/ph17010032 · Cited by 7
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.3 · Cited by 10
Relationship among structure, cytotoxicity, and Michael acceptor reactivity of quinocidin
Nakagawa, Y., Sawaki, Y., Miyanishi, W., Shimomura, S., Shibata, T., & Ojika, M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115308 · Cited by 5
Io, W.-S., & Wang, T. A. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00102 · Cited by 5
Drugging the undruggable: a computational chemist's view of KRAS G12C
Bodnarchuk, M. S., Cassar, D. J., Kettle, J. G., Robb, G. R., & Ward, R. A. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00055a · Cited by 6
Self-citationMichels, G., & Lehr, M. (2021) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2021.1925908 · Cited by 6
Gong, S., Hu, X., Chen, S., Sun, B., Wu, J., & Li, N. (2022) · Medicinal Research Reviews · doi:10.1002/med.21889 · Cited by 6
“The reactive groups that bind to proteins are commonly used or developed as warheads for drug development and shown in Figure 2.(25,26) For instance, acrylamide is the most popular reactive group and is a part of many covalent inhibitors, including afatinib, osimertinib,(27) and sotorasib.”
BackgroundTan, C., Kim, M., Park, I., Kim, Y., & Hong, S. (2022) · Angewandte Chemie · doi:10.1002/ange.202213857 · Cited by 5
Liu, S., Ye, H., Yi, L., & Xi, Z. (2023) · Chemical Communications · doi:10.1039/d2cc06419g · Cited by 4
Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease
Peng, T., Huang, G., Zhao, H., & Liu, J. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00564 · Cited by 5
Wang, Y., Luo, S., Sun, H., Huang, S., Shan, L., & Zhang, J.-F. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104347 · Cited by 4
Ernst, L. N., Stahlecker, J., Mier, F., Serafim, R. A. M., Wydra, V. R., Masberg, B., Jaag, S., Knappe, C., Lämmerhofer, M., Stehle, T., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70053 · Cited by 4
Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer
Yong, W. P., Zhang, S., Zhang, Z., Li, Z., Qin, Y., Qi, X., Wang, D., Zhang, Y., Li, J., Liu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01515 · Cited by 7
Jaman, S., Tasmi, S. F., Shahriar, I., & Halim, M. A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00508 · Cited by 8
Covalent chemistry in targeted protein degradation
Tan, J., Liang, Y., Shao, S., & Shen, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115777 · Cited by 4
Nyström, H. C., Valaka, A. P., Kalesse, H. A., Håversen, L., Olsson, T., Gunnarsson, A., Schweikart, F., Borén, J., & Grøtli, M. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03536 · Cited by 4
“2,8 In order to be selective, it is essential that the warhead possesses a well-balanced reactivity profile.”
Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres
Müller, P., Zimmer, C., Frey, A. F., Holzmann, G., Weldert, A. C., & Schirmeister, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031375 · Cited by 4
Lorell, J., IVANA, K., TANOTO, J. P. W., MICHAEL, M., JESCIKA, S., Gautama, N. R. P., Olivia, T. J. O. A., ALINA, K., Parikesit, A. A., & Sutanto, F. (2024) · Notulae Scientia Biologicae · doi:10.55779/nsb16111632 · Cited by 4
Assembly‐Glued Ligands and Warheads for Hypoxia‐Activatable Supramolecular Covalent Inhibitors
Hu, B., Qin, W., Wang, Y., Zhang, Z., Chen, N., Wang, H., Li, G., Shi, Y., & Yu, Z. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411179 · Cited by 5
Detection of an enzyme isomechanism by means of the kinetics of covalent inhibition
Adediran, S. A., Morrison, M. J., & Pratt, R. F. (2021) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2021.140681 · Cited by 4
Targeted Covalent Inhibitors for Novel Therapeutics
Zhang, J., Gao, W., Wang, Y., Chang, J., & Yu, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0243 · Cited by 4
Salazar-Estrada, I. D. J., Kamath, K. S., & Liu, F. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00155 · Cited by 4
Mutate and Conjugate: A Method to Enable Rapid In-Cell Target Validation
Thomas, A., Serafini, M. T., Grant, E. K., Coombs, E. A. J., Bluck, J. P., Schiedel, M., McDonough, M. A., Reynolds, J. K., Lee, B., Platt, M. A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00437 · Cited by 3
Sobinoff, A. P., Maro, S. D., Low, R. R. J., Benedetti, R., Tomassi, S., D’Aniello, A., Russo, R., Baglivo, I., Chianese, U., Pedone, P. V., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.11.008 · Cited by 4
Trapero, A., Pacitto, A., Chan, D. S., Abell, C., Blundell, T. L., Ascher, D. B., & Coyne, A. G. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126792 · Cited by 4
BIreactive: Expanding the Scope of Reactivity Predictions to Propynamides
Hermann, M. R., Tautermann, C. S., Sieger, P., Grundl, M. A., & Weber, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010116 · Cited by 5
Covalent Protein Inhibitors via Tyrosine Conjugation with Cyclic Imine Mannich ElectrophilesPreprint
Wang, S., Hadisurya, M., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-tvgn1 · Cited by 7
Rational Design of Stapled Covalent Peptide Modifiers of Oncoprotein E6 from Human Papillomavirus
Emanuelson, C., Naro, Y., Shade, O., Liu, M., Khare, S. D., & Deiters, A. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00878 · Cited by 6
“29,31,55 Prediction of the optimal warhead that balances on-and off-target reactivity is complicated by context-dependent influences on overall reactivity, including ligand and target conformation.”
An enzyme activity-based workflow for the identification and characterization of covalent inhibitors
Tang, B., Gladysheva, T. B., & Lang, P. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100250 · Cited by 3
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Qu, Z., Meke, F. N., Zhang, Z., Krabill, A. D., Muli, C. S., Jassim, B. A., Dong, J., Nguyen, Q. D., Bai, Y., Li, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202525126 · Cited by 8
Walker, J. C., Yan, K., & Derda, R. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00646 · Cited by 5
Wang, S., Wang, L., Hadisurya, M., Nia, S. S., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202516630 · Cited by 8
1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3
Jin, T., Zhao, Y., Xu, T., Fang, Y., Cui, Y., Liu, W., Xiong, Y., Ye, J., Luo, W., Hong, B., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116351 · Cited by 3
Ai, Y., Yang, Z., Yang, Z., Wan, S., Huang, C., Huang, C., Li, M., Li, Z., Zhang, J., & Zhang, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00458 · Cited by 3
Application of the Rumsfeld matrix to anticancer natural product target discovery
Bailly, C. (2024) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100023 · Cited by 2
Recent Progresses of Peptide Fluorescent Probes for Protein Analysis in Living Cells
Wu, X., Zhang, H., Li, M., Xia, F., & Lou, X. (2025) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c02671 · Cited by 3
Zhao, X., Gu, Y., Xie, Y., Wei, N., Fang, Z., Yan, X., & Wang, Q. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117867 · Cited by 3
Wang, Y., Gao, Q., Peng, Y., Yao, Q., & Zhang, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2193994 · Cited by 3
“In addition, compared to conventional noncovalent inhibitors, covalent inhibitors have shown prominent advantages including higher potency, reducing risk for drug resistance and sustained pharmaco-dynamics effect at lower therapeutic concentrations (Bauer, 2015; Lonsdale & Ward, 2018).”
BackgroundTakubo, H., Taniguchi, T., Iwanaga, K., & Nomura, Y. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1805816 · Cited by 3
2-Sulfonylpyrimidines: Reactivity Adjustable Agents for Cysteine ArylationPreprint
Pichon, M. M., Drelinkiewicz, D., Lozano, D., Moraru, R., Hayward, L., Jones, M., Mccoy, M., Allstrum-Graves, S., Balourdas, D.-I., Joerger, A. C., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-cx8vk · Cited by 3
Bonus, M., Greb, J., Majmudar, J. D., Boehm, M., Korczynska, M., Nazemi, A., Mathiowetz, A. M., & Gohlke, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5098975 · Cited by 3
An Enzyme-Catalyzed Polymerization Strategy Disrupts Protein Homeostasis for Improved Tumor Therapy
Xu, Y., Zhang, Y., Song, B., Liu, Y., Hao, Y., Zhongyu, D., Qiao, Z., & Wang, H. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00928 · Cited by 2
Accelerating Covalent Drug Discovery: Recent Advances in Covalent Docking Tools
Li, S. W., Du, H., Zhang, H., Zhang, X., Ye, Y., Shen, C., Hou, T., & Pan, P. (2025) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70062 · Cited by 4
“When targeting catalytic residues, inhibitors often mimic natural substrates, engaging in competitive binding [2, 5, 6].”
InfluentialCovalent drugs in development for immune-mediated diseases
Sung, L. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.03.001 · Cited by 4
Qin, H., & Tao, X.-F. (2023) · Synthesis · doi:10.1055/s-0041-1738449 · Cited by 2
Practical Perspectives and Roles of XRD in Drug Discovery: A Review
Mehta, A., Makhija, R., Barik, P., Dhiman, S., Gupta, G. D., & Asati, V. (2024) · Current Analytical Chemistry · doi:10.2174/0115734110296435240323113938 · Cited by 2
Guerra-Rodríguez, M., López-Rojas, P., Amesty, Á., Aranda-Tavío, H., Brito‐Casillas, Y., Estévez‐Braun, A., Fernández‐Pérez, L., Guerra, B., & Recio, C. (2022) · Cancers · doi:10.3390/cancers14215174 · Cited by 3
“This cytostatic condition with slow but durable antiproliferative activity is generally associated with strong connections between compounds and targets or posttranscriptional and posttranslational effects after binding [52,53].”
BackgroundThe art of suicidal molecular seduction for targeting drug resistance
Moshafi, M. H., Ghasemshirazi, S., & Abiri, A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109676 · Cited by 3
Chemical proteomics of reactive molecules
Wang, L., & Yao, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00008-8 · Cited by 2
A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors
Kondo, A., Fujimoto, K. J., & Yanai, T. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp01723k · Cited by 2
Ferreira, L. L. G., & Andricopulo, A. D. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc141.pub2 · Cited by 2
Qin, Z., Zhu, Y., & Xiang, Y. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-nd0r2 · Cited by 2
Guerra-Rodríguez, M., López-Rojas, P., Amesty, Á., Aranda-Tavío, H., Brito‐Casillas, Y., Estévez‐Braun, A., Fernández‐Pérez, L., Guerra, B., & Recio, C. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197933 · Cited by 2
Nucleophilie von Glutathion als Bindeglied zur Reaktivität von Michael‐Akzeptoren
Mayer, R. J., & Ofial, A. R. (2019) · Angewandte Chemie · doi:10.1002/ange.201909803 · Cited by 2
Srinivasan, B. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.08.004 · Cited by 3
Naylon, S. H., Richaud, A. D., Zhao, G., Bui, L., Dufresne, C. P., Wu, C., Wangpaichitr, M., Savaraj, N., & Roche, S. P. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00174e · Cited by 1
“Acrylamides are physiologically stable, yet powerful and selective Michael acceptors that have demonstrated efficacy in a number of covalent drugs 86,87 in particular targeting surface exposed lysines.”
Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
Zeng, J., Luo, Z., Zhao, T., Xia, C., Liu, F., Li, N., Qu, L., & Wang, C. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70067 · Cited by 1
“…in the field of tumor resistance, compounds such as afatinib and ibrutinib are well used in clinical practice and have great advantages in improving selectivity, increasing activity, and reducing drug resistance (Li et al. 2008; Lonsdale and Ward 2018; Lagoutte et al. 2017; Ma et al. 2019).”
Shen, R., Zhang, B., Liu, J., Yi, M., Chen, Y., & Fang, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01090j · Cited by 1
Li, L., Luo, B., Wang, X., Jian, Z., Liu, H., Ren, B., 乔文良, Luo, Y., & Yang, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118008 · Cited by 1
Cerutti, J. P., Canepa, J. I. E., Diniz, L. A., Larrea, S. C. V., Santos, V. C., Alonso, G., Ferreira, R. S., Dehaen, W., & Quevedo, M. A. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01849 · Cited by 1
Fatima, I., Safhi, A. Y., Alsalhi, A., Hanbashi, A., Jali, A. M., Alsabei, H. M., Alshabrmi, F. M., & Sabei, F. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152973 · Cited by 1
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Qu, Z., Meke, F. N., Zhang, Z., Krabill, A. D., Muli, C. S., Jassim, B. A., Dong, J., Nguyen, Q. D., Bai, Y., Li, J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202525126 · Cited by 1
Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening
Deng, Y., Li, S. P., Wang, L., Lin, J., Fu, H., Li, J., & Chen, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02496 · Cited by 1
Li, R., Shi, Q., Zhu, M., Cao, W., Tao, Y., & Shen, L. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100239 · Cited by 1
Zhao, X., Wei, N., Fang, Z., Xie, Y., Yan, X. Y., & Wang, Q. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02215 · Cited by 2
Liu, W., Guo, Q., Ma, L., Li, R., Ren, J., Jiang, H., (36685), G. W., & Zeng, R. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174744 · Cited by 1
Targeting FLT3 in Acute Myeloid Leukemia: Structural Insights and Key Challenges
da Silva, M. R., Lima, L. C. V., & Barbosa, M. L. D. C. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00021 · Cited by 1
Schwer, M., Aldea, S., Engelhardt, M., Stahlecker, J., Rheinganz, J., Langkamp, A., & Boeckler, F. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s598622 · Cited by 1
Enhancing De Novo Designed Peptides and Proteins via Irreversible Covalent Isoquinolinium Capture
Levine, P. M., Erickson, P. W., Craven, T. W., Balana, A. T., Hicks, D. R., Ahn, G., Kim, C. J., Brandenburg, L. S., Yang, W., Erickson, D. P. J., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00584 · Cited by 1
“4,5 Covalent mechanisms largely circumvent short half-lives in vivo as they decouple drug efficacy from pharmacokinetics, resulting in prolonged target engagement and enhance drug binding off-rates.”
Computational support of structure-based targeted covalent inhibitor design
Abel, R., & Friesner, R. A. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.01.001 · Cited by 2
Structure-based methods in drug design
Guruprasad, L., Andola, P., Banerjee, A., Durgam, L., & Naresh, G. K. R. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18638-7.00003-7 · Cited by 2
Serine and Metal-Dependent meta-Cleavage Product Hydrolases
Ruzzini, A. C., Kuatsjah, E., & Eltis, L. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14655-4 · Cited by 1
Takubo, H., Ishikawa, T., Taniguchi, T., Iwanaga, K., & Nomura, Y. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1809030 · Cited by 1
Metadata
- Authors
- Lonsdale, R., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 11
- Pages
- 3816-3830
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2796108867
- Cited by
- 344
- References
- 49
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 46 · 2023: 49 · 2022: 47 · 2021: 45 · 2020: 46 · 2019: 31 · 2018: 8
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- targeted covalent inhibitors, covalent inhibition, structure-based drug design, reactive functional groups, small molecule inhibitors, inhibitor selectivity, covalent drug discovery
- MeSH terms
- Humans, Drug Design, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.